The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 21: 3061 - 3066

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.21.016

Drugs and Clinic Practice

Efficacy of bevacizumab combined with raltitrexed in the treatment of unresectable hepatocellular carcinoma and its influence on adverse reactions and survival rate

  • Hua WANG ,
  • Yue HEI ,
  • Miao SUN ,
  • Yanchuang SUN ,
  • Juan HAN ,
  • Juanhua. SUN
Expand
  • Department of Oncology，the First Affiliated Hospital of Air Force Medical University，Xi'an 710032，Shaanxi，China

Received date: 2024-06-14

  Online published: 2024-11-19

Fold

Abstract

Objective To investigate the efficacy of bevacizumab combined with raltitrexed in the treatment of unresectable hepatocellular carcinoma （HCC） and its effect on adverse reactions and survival rate. Methods A retrospective analysis was performed on 71 patients with unresectable hepatocellular carcinoma admitted to the oncology department of our hospital from February 2020 to June 2022. Among them， 35 cases were treated with raltitrexed as control group， and 36 cases were treated with bevacizumab combined with raltitrexed as observation group. All patients received transcatheter arterial chemoembolization （TACE）. After 1 month of treatment， the short-term treatment effect of the two groups was evaluated. The adverse reactions of the two groups were observed. Follow-up review was performed to record progression free survival （PFS） and overall survival（OS） in both groups. Results After 1 month of treatment， the disease control rate（DCR） and objective response rate（ORR） of control group were 74.29% and 45.71% respectively. The DCR and ORR of observation group were 83.33% and 55.56% respectively. There was no significant difference in short-term efficacy between the two groups （P > 0.05）. Following treatment， the vascular endothelial growth factor （VEGF）level in the observation group was considerably lower than in the control group （P < 0.05）. After treatment， 18 months of follow-up， OS curve showed： observation group OS was 50.00%， control group OS was 31.40%； PFS curve showed： observation group PFS was 43.33%， control group PFS was 26.92%. Using the Log-rank test， between the two groups， there was a statistically significant difference in OS （χ 2 = 4.381， P = 0.036）， although there was no statistically significant difference in PFS between the two groups （χ 2 = 3.264， P = 0.071）. There was no significant difference in adverse reactions between the two groups （P > 0.05）. Conclusion Bevacizumab combined with raltitrexed can reduce tumor neovascularization， inhibit tumor growth and spread， prolong the survival time of patients， and do not increase adverse drug reactions.

Key words： bevacizumab; Raltitrexed; unresectable hepatocellular carcinoma; adverse reactions; survival rate

Cite this article

Hua WANG , Yue HEI , Miao SUN , Yanchuang SUN , Juan HAN , Juanhua. SUN . Efficacy of bevacizumab combined with raltitrexed in the treatment of unresectable hepatocellular carcinoma and its influence on adverse reactions and survival rate[J]. The Journal of Practical Medicine, 2024 , 40(21) : 3061 -3066 . DOI: 10.3969/j.issn.1006-5725.2024.21.016

References

1 SUNG H， FERLAY J， SIEGEL R L， et al. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin， 2021， 71（3）：209-249. doi:10.3322/caac.21660
2 吴健，曹林平. 机器学习在肝移植中的应用［J］. 器官移植，2022，13（6）：722-729.
3 汪国营，何才华. 肝移植治疗肝内胆管癌的研究进展［J］. 器官移植，2023，14（6）：789-796.
4 MORAN A， RAMOS L F， PICADO O， et al. Hepatocellular carcinoma： Resection with adjuvant hepatic artery infusion therapy vs resection alone． A systematic review and meta-analysis［J］.J Surg Oncol， 2019， 119（4）：455-463. doi:10.1002/jso.25338
5 陈示光. 常规肝动脉化疗栓塞单用及联合药物洗脱微球栓塞治疗不可切除大肝细胞癌的疗效和安全性比较［J］. 临床肝胆病杂志，2021，37（5）：998.
6 ZOU H， ZHU C Z， WANG C， et al. Recurrence of Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy［J］.Am J Med Sci， 2017， 354（3）：262-267. doi:10.1016/j.amjms.2017.05.014
7 SIEGHART W， HUCKE F， PECK-RADOSAVLJEVIC M.Transarterial chemoembolization： Modalities，indication，and patient selection［J］. J Hepatol， 2015， 62（5）：1187-1195. doi:10.1016/j.jhep.2015.02.010
8 马玉洁， 陈冬娜， 梁向伟， 等. 雷替曲塞联合伊立替康治疗晚期结直肠癌的临床观察［J］. 中华结直肠疾病电子杂志， 2020， 9（4）：349-354.
9 徐金发， 蔡清， 章秀芳， 等. 贝伐珠单抗与奥沙利铂联合雷替曲塞治疗晚期结直肠癌临床效果观察［J］. 临床军医杂志， 2021， 49（2）：183-184， 187.
10 WU J Y， WU X N， DING L， et al. Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer［J］. Chin Med J （Engl）， 2010， 123（7）：901-906.
11 中国抗癌协会肝癌专业委员会， 中华医学会肝病学分会肝癌学组， 中国抗癌协会病理专业委员会， 等. 原发性肝癌规范化病理诊断指南（2015年版）［J］.中华肝脏病杂志， 2015， 23（5）：321-327.
12 SCHWARTZ L H， SEYMOUR L， LITIèRE S， et al. RECIST 1.1 standardisation and disease-specific adaptations： Perspectives from the RECIST working group［J］. Eur J Cancer， 2016， 62： 138-145. doi:10.1016/j.ejca.2016.03.082
13 BRAY F， FERLAY J， SOERJOMATARAM I， et al.Global cancer statistics 2018： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2018， 68（6）：394-424. doi:10.3322/caac.21492
14 GLOBAL BURDEN OF DISEASE LIVER CANCER COLLABORATION， AKINYEMIJU T， ABERA S， et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global， Regional， and National Level： Results From the Global Burden of Disease Study 2015［J］. JAMA Oncol， 2017， 3（12）：1683-1691.
15 金志成，张齐，朱海东，等. 肝癌根治性切除术后辅助性TACE治疗的研究进展［J］. 中华肝脏病杂志， 2022， 30（3）：340-344.
16 CHANG Y， JEONG S W， JANG J Y， et al. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma［J］. Int J Mol Sci， 2020， 21（21）：8165. doi:10.3390/ijms21218165
17 孙健， 王甦. 雷替曲塞与表柔比星在不可切除原发性肝癌经导管肝动脉化疗栓塞术中的疗效比较［J］. 实用临床医药杂志， 2020， 24（11）：87-91， 96.
18 RAOUL J L， FORNER A， BOLONDI L， et al. Updated use of TACE for hepatocellular carcinoma treatment： How and when to use it based on clinical evidence［J］. Cancer Treat Rev， 2019， 72：28-36. doi:10.1016/j.ctrv.2018.11.002
19 LLOVET J M， DE BAERE T， KULIK L， et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma［J］. Nat Rev Gastroenterol Hepatol， 2021， 18（5）：293-313. doi:10.1038/s41575-020-00395-0
20 GRETEN T F， MAUDA-HAVAKUK M， HEINRICH B， et al. Combined locoregional-immunotherapy for liver cancer［J］. J Hepatol， 2019， 70（5）：999-1007. doi:10.1016/j.jhep.2019.01.027
21 ZHOU M， LIU B， SHEN J. Immunotherapy for hepatocellular carcinoma［J］. Clin Exp Med， 2023， 23（3）：569-577. doi:10.1007/s10238-022-00874-5
22 OURA K， MORISHITA A， TANI J， et al. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma： A Review［J］. Int J Mol Sci， 2021， 22（11）： 5801. doi:10.3390/ijms22115801
23 HABER P K， PUIGVEHí M， CASTET F， et al. Evidence-based management of hepatocellular carcinoma： Systematic review and meta-analysis of randomized controlled trials （2002-2020） ［J］. Gastroenterology， 2021， 161（3）：879-898. doi:10.1053/j.gastro.2021.06.008
24 邱作栋， 余会丽， 户军燕， 等. 信迪利单抗联合贝伐珠单抗治疗不可切除肝细胞肝癌的疗效及安全性［J］. 实用癌症杂志， 2023， 38（12）：2034-2037.
25 SU G L， ALTAYAR O， O'SHEA R， et al. Aga clinical practice guideline on systemic therapy for hepatocellular carcinoma［J］. Gastroenterology， 2022， 162（3）：920-934. doi:10.1053/j.gastro.2021.12.276
26 PINATO D J， MURRAY S M， FORNER A， et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma： Implications for immunotherapy［J］. J Immunother Cancer， 2021， 9（9）： e003311. doi:10.1136/jitc-2021-003311
27 李龙， 郑振东， 杜成， 等. 贝伐珠单抗联合TACE治疗中晚期肝细胞癌的临床疗效观察［J］. 肝脏， 2022， 27（3）：281-283， 310.
28 董明君， 戴晓宇， 赖福记， 等. 贝伐珠单抗联合雷替曲塞或卡培他滨治疗老年晚期结直肠癌的疗效及安全性观察［J］. 浙江医学， 2019， 41（23）：2540-2542.
29 胡钧文， 杨清梅， 华杨， 等. 雷替曲塞与氟尿嘧啶对不可切除肝癌患者的疗效观察［J］. 河北医药， 2023， 45（5）：715-718.
Options
Outlines

/

〈 〉